Bullish
$SESN There is a good chance the FDA phase 4 trial for increased label expansion could lead to FL treatment or at least substitute for non-responsive BCG patients. The data suggests that Vicinium works better in patients that receive less BCG. That means that if the FDA moves Vici for first line treatment, patients can still get BCG as an alternative for non-response which has way more side effects / high cystectomy rates.
  • 15
  • 5